JP4095557B2 - 尿酸を削減するためのヒスチジンおよびアラニンのジペプチドを含有する組成物および尿酸を削減するための医薬の製造のためのジペプチドの使用 - Google Patents
尿酸を削減するためのヒスチジンおよびアラニンのジペプチドを含有する組成物および尿酸を削減するための医薬の製造のためのジペプチドの使用 Download PDFInfo
- Publication number
- JP4095557B2 JP4095557B2 JP2004006763A JP2004006763A JP4095557B2 JP 4095557 B2 JP4095557 B2 JP 4095557B2 JP 2004006763 A JP2004006763 A JP 2004006763A JP 2004006763 A JP2004006763 A JP 2004006763A JP 4095557 B2 JP4095557 B2 JP 4095557B2
- Authority
- JP
- Japan
- Prior art keywords
- uric acid
- composition
- dipeptide
- dipeptides
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010016626 Dipeptides Proteins 0.000 title claims description 49
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims description 49
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims description 49
- 229940116269 uric acid Drugs 0.000 title claims description 49
- 239000000203 mixture Substances 0.000 title claims description 35
- 239000003814 drug Substances 0.000 title claims description 15
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 title claims description 11
- 235000004279 alanine Nutrition 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 title claims description 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 title description 3
- 108010085443 Anserine Proteins 0.000 claims description 20
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 claims description 20
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 20
- 241000210053 Potentilla elegans Species 0.000 claims description 20
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims description 20
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical group [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 20
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 19
- 108010087806 Carnosine Proteins 0.000 claims description 19
- 229940044199 carnosine Drugs 0.000 claims description 19
- 230000029142 excretion Effects 0.000 claims description 15
- 201000005569 Gout Diseases 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 10
- -1 cinchophane Chemical compound 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- DVEQCIBLXRSYPH-UHFFFAOYSA-N 5-butyl-1-cyclohexylbarbituric acid Chemical compound O=C1C(CCCC)C(=O)NC(=O)N1C1CCCCC1 DVEQCIBLXRSYPH-UHFFFAOYSA-N 0.000 claims description 5
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 5
- 229960003459 allopurinol Drugs 0.000 claims description 5
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical group CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 claims description 5
- 229960002529 benzbromarone Drugs 0.000 claims description 5
- 229950003872 bucolome Drugs 0.000 claims description 5
- 229960001338 colchicine Drugs 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 3
- 102000015636 Oligopeptides Human genes 0.000 claims description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 2
- 229960004203 carnitine Drugs 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 description 10
- 229960002885 histidine Drugs 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- CCLQKVKJOGVQLU-QMMMGPOBSA-N L-homocarnosine Chemical compound NCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 CCLQKVKJOGVQLU-QMMMGPOBSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 108700002498 homocarnosine Proteins 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- CYZKJBZEIFWZSR-LURJTMIESA-N N(alpha)-methyl-L-histidine Chemical compound CN[C@H](C(O)=O)CC1=CNC=N1 CYZKJBZEIFWZSR-LURJTMIESA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- ANRUJJLGVODXIK-UHFFFAOYSA-N 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide Chemical compound NCCC(=O)NCCC1=CN=CN1 ANRUJJLGVODXIK-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- SLRNWACWRVGMKD-QMMMGPOBSA-N Balenine Chemical compound CN1C=NC(C[C@H](N=C(O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-QMMMGPOBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010028690 Fish Proteins Proteins 0.000 description 1
- 206010061974 Gastrointestinal obstruction Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 108700021352 carcinine Proteins 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 208000016334 muscle symptom Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
Description
ボルディレフ(Boldyrev)AA.ら著、Mol Chem Neuropathol 1993年5〜6月、19(1〜2):185〜192頁 ファング(Huang)SCとクオ(Kuo)JC著、Proc Natl Sci Counuc Repub China B.、2000年10月、24(4):193から201頁 キャンドリッシュ(Candlish)JKとダス(Das)NP著、1996年9月、9(2〜3):117〜123頁 マクファスナーレン(MacFarlane)N著、J Mol Cell Cardiol.、1991年11月、23(11):1205〜1207頁 ナガイ(Nagai)Kとスダ(Suda)T著、1988年8月、10(8):497〜507頁 ホリデイ(Holliday)Rとマクファーランド(McFarland)GA著、Br J Cancer、1996年4月、73(8):966〜971頁 ボルディレフ(Boldyrev)AA.とセバリアン(Severin)SE著、Adv Enzyme Regual、1990年、30:175〜194頁 チャン(Chan)WKら著、1994年7月、29(7):461〜466頁 タン(Tan)KMとキャンディッシュ(Candlish)JK、1998年8月、20(4):239〜244頁 カズオ・サカイ(Kazuo Sakai)ら著、"Development of Industrial Refining and Separation Technology for Dipeptides, Anserin and Carnosine, from Fish Boiling Juice and Their Functional Property(魚煮沸汁からのジペプチド類、アンセリンおよびカルノシンの工業的精製および分離の開発、およびそれらの機能的特性)"、焼津水産化学工業株式会社
Claims (19)
- ヒスチジンまたはその機能的等価物およびアラニンまたはその機能的等価物から成る有効量の1種類以上のジペプチドを含む、対象における尿酸を削減するための組成物であって、ジペプチドがカルノシンおよびアンセリンである組成物。
- カルノシンおよびアンセリンをそれぞれ、ジペプチドの総量の約5〜30%w/w、および約95〜70%w/w含む、請求項1に記載の組成物。
- カルノシンおよびアンセリンをそれぞれ、ジペプチドの総量の約7%w/w、および約90%w/w含む、請求項2に記載の組成物。
- 経口または非経口の経路によって対象に投与または適用される、請求項1に記載の組成物。
- 1日約8mg〜50mgの量のジペプチドを提供するように投与または適用される、請求項1に記載の組成物。
- 1日約10mg〜45mgの量のジペプチドを提供するように投与または適用される、請求項5に記載の組成物。
- オリゴペプチド、遊離アミノ酸、カルニチン、および薬学的または生理学的に許容される賦形剤をさらに含む、請求項1に記載の組成物。
- 尿酸排泄剤と併用し、同時に、または連続的に対象に投与または適用される、請求項1に記載の組成物。
- 尿酸排泄剤が、ベンズブロマロン、ブロべネシド、アロプリノール、ブコロム、シンコファン、およびコルヒチンから選択される、請求項8に記載の組成物。
- 痛風の治療のための医薬品として用いられる、請求項1に記載の組成物。
- 患者の尿酸を削減するための医薬の製造のためのカルノシンおよびアンセリンの使用。
- カルノシンおよびアンセリンをそれぞれ、ジペプチドの総量の約5〜30%w/w、および約95〜70%w/w含む、請求項11に記載の使用。
- カルノシンおよびアンセリンをそれぞれ、ジペプチドの総量の約7%w/w、および約90%w/w含む、請求項12に記載の使用。
- 経口または非経口の経路によって対象に投与または適用される医薬の製造のための請求項11に記載の使用。
- 1日約8mg〜50mgの量のジペプチドを提供するように投与または適用される医薬の製造のための請求項11に記載の使用。
- 1日約10mg〜45mgの量のジペプチドを提供するように投与または適用される医薬の製造のための請求項15に記載の使用。
- 痛風の治療のための医薬の製造に用いられる、請求項11に記載の使用。
- 尿酸排泄剤と併用し、同時に、または連続的に投与される医薬の製造のための請求項11に記載の使用。
- 尿酸排泄剤が、ベンズブロマロン、ブロべネシド、アロプリノール、ブコロム、シンコファン、およびコルヒチンから選択される、請求項18に記載の使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/449,053 US20040242491A1 (en) | 2003-05-30 | 2003-05-30 | Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004359663A JP2004359663A (ja) | 2004-12-24 |
JP4095557B2 true JP4095557B2 (ja) | 2008-06-04 |
Family
ID=33451680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004006763A Expired - Lifetime JP4095557B2 (ja) | 2003-05-30 | 2004-01-14 | 尿酸を削減するためのヒスチジンおよびアラニンのジペプチドを含有する組成物および尿酸を削減するための医薬の製造のためのジペプチドの使用 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20040242491A1 (ja) |
JP (1) | JP4095557B2 (ja) |
CN (1) | CN100441220C (ja) |
TW (1) | TWI280136B (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7708998B2 (en) * | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
AU2007208819B2 (en) * | 2006-01-24 | 2012-06-07 | Nippon Zoki Pharmaceutical Co., Ltd. | Novel histidine derivative |
JP2007297288A (ja) * | 2006-04-27 | 2007-11-15 | Yaizu Suisankagaku Industry Co Ltd | Hprt産生促進組成物、及び該組成物を含有するキサンチン尿症の予防及び/又は改善剤 |
JP2008088162A (ja) * | 2006-09-06 | 2008-04-17 | Takahashi Gakuen | 睡眠補助剤および睡眠補助食品 |
CN101278928B (zh) * | 2007-04-06 | 2011-09-07 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 含左卡尼汀或其衍生物的药物组合物及其用途 |
KR101438012B1 (ko) * | 2007-07-23 | 2014-09-04 | 니폰 조키 세야쿠 가부시키가이샤 | 신규 히스티딘 유도체 |
JP2009078980A (ja) * | 2007-09-25 | 2009-04-16 | Takahashi Gakuen | 疼痛緩和剤および疼痛緩和補助食品 |
JP2009102248A (ja) * | 2007-10-22 | 2009-05-14 | Lytone Enterpprise Inc | 血中尿酸を急速に低減させるための医薬組成物およびパッケージならびに血中尿酸を急速に低減させるためのアンセリンの使用 |
EP2052735B1 (en) | 2007-10-22 | 2016-05-11 | Lytone Enterprise, Inc. | Pharmaceutical composition and kit comprising anserine for rapidly reducing uric acid in blood |
UA109638C2 (uk) * | 2008-03-13 | 2015-09-25 | Сполуки та спосіб зниження рівня сечової кислоти | |
JP5437672B2 (ja) * | 2008-03-31 | 2014-03-12 | ライオン株式会社 | 血清中尿酸値の低減剤 |
WO2012027277A2 (en) * | 2010-08-21 | 2012-03-01 | Hydropep, Llc | Compositions for reducing the deleterious effects of stress and aging |
CN102784388A (zh) * | 2012-08-03 | 2012-11-21 | 东莞市照燕生物科技有限公司 | 一种降低尿酸的营养保健品 |
CN103719990B (zh) * | 2013-12-17 | 2018-10-12 | 浙江现代中药与天然药物研究院有限公司 | 一种含有螺旋藻和鲣鱼骨提取物的功能性饮料 |
CN104068288B (zh) * | 2014-07-25 | 2016-08-24 | 许伟琦 | 一种防尿路结石的饲料添加剂 |
CN104337836B (zh) * | 2014-09-30 | 2018-05-15 | 华南理工大学 | 一种具有降尿酸功效的柴鱼蛋白水解物制备方法 |
CN104784210A (zh) * | 2015-04-30 | 2015-07-22 | 无限极(中国)有限公司 | 一种具有降尿酸功效的鲣鱼提取物的制备方法及其应用 |
CN104789623A (zh) * | 2015-04-30 | 2015-07-22 | 无限极(中国)有限公司 | 一种蛋白肽的制备方法、蛋白肽及其应用 |
CN105126067B (zh) * | 2015-09-30 | 2018-05-22 | 北京知蜂堂健康科技股份有限公司 | 一种降尿酸的组合物及其用途 |
CN105901335A (zh) * | 2016-05-25 | 2016-08-31 | 中国农业大学 | 一种促进猪骨骼肌生长的饲料添加剂及其应用 |
CN106389439A (zh) * | 2016-12-21 | 2017-02-15 | 郑州莉迪亚医药科技有限公司 | 一种治疗肝硬化腹水的中西药组合及其制备方法和应用 |
CN108065166A (zh) * | 2017-12-21 | 2018-05-25 | 深圳万和制药有限公司 | 具有降尿酸作用的固体饮料组合物 |
CN108887549A (zh) * | 2018-06-29 | 2018-11-27 | 南京医科大学 | 抗疲劳固体饮料、制备方法及其主料组合物 |
CN110038119A (zh) * | 2019-04-28 | 2019-07-23 | 杭州泽健医药科技有限公司 | 一种具有降尿酸和抗疲劳作用的药物组合物 |
CN110916200A (zh) * | 2019-12-02 | 2020-03-27 | 广东微量元素生物科技有限公司 | 一种降尿酸组合物及其制备方法 |
CN112023019A (zh) * | 2020-09-15 | 2020-12-04 | 上海健康医学院 | 一种具有降高尿酸作用的含活性多糖药物及其制备方法 |
US20220168380A1 (en) * | 2020-11-27 | 2022-06-02 | Lytone Enterprise, Inc. | Formulations for treating cramps and spasms |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0920660A (ja) | 1995-07-04 | 1997-01-21 | Suntory Ltd | 抗ストレス組成物 |
JP3877807B2 (ja) * | 1996-07-03 | 2007-02-07 | ゼリア新薬工業株式会社 | 口内炎治療・予防剤 |
JP2000290187A (ja) | 1999-04-05 | 2000-10-17 | Toshio Sato | キトサン入りソフトカプセル及びその製造方法 |
US6310188B1 (en) | 2000-01-24 | 2001-10-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for producing chitin or chitosan |
DE10043456A1 (de) * | 2000-09-04 | 2002-03-14 | Merck Patent Gmbh | Verwendung von Ectoin oder Ectoin-Derivaten zur Stabilisierung von p53 |
AU2001296307A1 (en) * | 2000-09-25 | 2002-04-08 | Millennium Pharmaceuticals, Inc. | 55054, a human metalloprotease and uses therefor |
US6855727B2 (en) * | 2000-12-04 | 2005-02-15 | Yaizu Suisankagaku Industry Co., Ltd. | Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect |
JP2002338473A (ja) | 2001-05-15 | 2002-11-27 | Yaizu Suisankagaku Industry Co Ltd | 抗疲労組成物 |
-
2003
- 2003-05-30 TW TW092114798A patent/TWI280136B/zh not_active IP Right Cessation
- 2003-05-30 US US10/449,053 patent/US20040242491A1/en not_active Abandoned
- 2003-12-17 CN CNB2003101212945A patent/CN100441220C/zh not_active Expired - Lifetime
-
2004
- 2004-01-14 JP JP2004006763A patent/JP4095557B2/ja not_active Expired - Lifetime
-
2006
- 2006-12-22 US US11/644,336 patent/US7498301B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20070099846A1 (en) | 2007-05-03 |
TW200425907A (en) | 2004-12-01 |
US20040242491A1 (en) | 2004-12-02 |
TWI280136B (en) | 2007-05-01 |
JP2004359663A (ja) | 2004-12-24 |
CN100441220C (zh) | 2008-12-10 |
CN1572318A (zh) | 2005-02-02 |
US7498301B2 (en) | 2009-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4095557B2 (ja) | 尿酸を削減するためのヒスチジンおよびアラニンのジペプチドを含有する組成物および尿酸を削減するための医薬の製造のためのジペプチドの使用 | |
US20060205634A1 (en) | Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease | |
EP0865294B1 (en) | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions | |
ES2673672T3 (es) | Composiciones tripeptídicas y su uso para el tratamiento de la diabetes | |
JP2009513647A (ja) | 分岐鎖アミノ酸の使用方法 | |
CN1917889A (zh) | 镓在治疗炎性关节炎中的用途 | |
JP2009102248A (ja) | 血中尿酸を急速に低減させるための医薬組成物およびパッケージならびに血中尿酸を急速に低減させるためのアンセリンの使用 | |
JP2010138133A (ja) | 微細藻類スピルリナ由来の血圧降下ペプチド及びその製造方法 | |
CA2717322C (en) | Apoaequorin-containing compositions and methods of using same | |
JPWO2002060431A1 (ja) | 炎症性疾患治療予防剤 | |
JP2024045186A (ja) | アポエクオリンおよびビタミンd含有組成物およびそれらの使用方法 | |
JP2006256985A (ja) | 貝殻から得られるカルシウム塩結晶化抑制蛋白とその製造方法、ならびにその利用 | |
JPH01265028A (ja) | 特発性血小板減少性紫斑病治療剤 | |
JPH0656674A (ja) | 血圧降下用の食品添加物質および抗高血圧剤 | |
EP2052735B1 (en) | Pharmaceutical composition and kit comprising anserine for rapidly reducing uric acid in blood | |
JP5317456B2 (ja) | 内因性オピオイドペプチドの血中分泌促進用組成物 | |
EA020034B1 (ru) | Способ немедикаментозного лечения атеросклероза | |
JP3972104B2 (ja) | 新規なヘクサペプチド及びアンジオテンシン変換酵素阻害剤 | |
JP2866872B2 (ja) | 血圧降下剤 | |
JP3709425B2 (ja) | 新規なトリペプチドおよびアンジオテンシン変換酵素阻害剤 | |
WO2005092363A1 (ja) | オリゴペプチドを用いた糖尿病合併症の予防・治療剤 | |
WO2002074303A1 (fr) | Compositions d'acides amines pour ameliorer l'insuffisance renale | |
JP2006028065A (ja) | アルドステロン分泌阻害剤、アンジオテンシン変換酵素阻害剤及び血圧降下剤 | |
WO2001007077A1 (fr) | Agents anti-ulcereux |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070522 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070815 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070925 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080220 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080307 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110314 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4095557 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130314 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140314 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |